|
|
||||||||
Experimental Neurobiology and Neuroimmunology Units, Division of Neurology, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden
NO is involved in the regulation of immune responses. The role of
NO in the pathogenesis of experimental allergic encephalomyelitis (EAE)
is controversial. In this study, 3-morpholinosydnonimine (SIN-1), an NO
donor, was administered to Lewis rats on days 57 postimmunization,
i.e., during the incipient phase of EAE. SIN-1 reduced clinical signs
of EAE compared with those in PBS-treated control rats and was
accompanied by reduced ED1+ macrophages and
CD4+ T cell infiltration within the CNS. Blood mononuclear
cells (MNC) obtained on day 14 postimmunization revealed that SIN-1
administration enhanced NO and IFN-
production by blood MNC and
suppressed Ag- and mitogen-induced proliferative responses. MHC class
II, B7-1 and B7-2 were down-regulated in SIN-1-treated EAE rats.
Simultaneously, frequencies of apoptotic cells among blood MNC were
increased. In vivo, SIN-1 is likely to behave as an NO donor.
Administration of SIN-1 induced NO production, but did not affect
superoxide and peroxynitrite formation. Enhanced NO production during
the priming phase of EAE thus promotes apoptosis, down-regulates
disease-promoting immune reactivities, and ameliorates clinical EAE,
mainly through SIN-1-derived NO, without depending on NO
synthase.
This article has been cited by other articles:
![]() |
P. J. McNamara, P. Murthy, C. Kantores, L. Teixeira, D. Engelberts, T. van Vliet, B. P. Kavanagh, and R. P. Jankov Acute vasodilator effects of Rho-kinase inhibitors in neonatal rats with pulmonary hypertension unresponsive to nitric oxide Am J Physiol Lung Cell Mol Physiol, February 1, 2008; 294(2): L205 - L213. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhu, Y. Bando, S. Xiao, K. Yang, A. C. Anderson, V. K. Kuchroo, and S. J. Khoury CD11b+Ly-6Chi Suppressive Monocytes in Experimental Autoimmune Encephalomyelitis J. Immunol., October 15, 2007; 179(8): 5228 - 5237. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |